Actualités objectives et pratiques en psychopharmacologie

Quick Takes

Cinq résumés de recherche en psychiatrie adulte, chaque mois. Formation médicale continue disponible pour les membres Argent et Or.

Expert Consultations

Nous interviewons des experts qui partagent des conseils cliniques précieux pour votre pratique. Formation médicale continue disponible pour les membres Argent et Or.

Video Lectures

Une sélection de sections pratiques extraites de nos cours vidéo. Formation CME disponible pour les membres Bronze, Argent et Or.

RECENT PUBLICATIONS

OCD résistant au traitement : Des SSRIs à l’augmentation

1.25 CMEs
A guide to management of treatment-resistant OCD, covering proper diagnostic criteria, evidence-based SSRI dosing protocols, systematic augmentation strategies, and advanced interventions such as TMS, DBS, and ablative surgery for refractory cases.
Robert Hudak, M.D.
University of Pittsburgh
68.55 minutes en 12 sections

[FR] Trazodone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

0.50 CMEs
This guide provides a comprehensive review of trazodone, a serotonin antagonist and reuptake inhibitor (SARI) FDA-approved for depression but predominantly prescribed off-label for insomnia, covering its dose-dependent pharmacology, clinical uses, drug interactions, side effects including priapism and QT prolongation, and special population considerations.
Sebastián Malleza, M.D.
Psychopharmacology Institute
Afficher plus d'informations

Lithium : comment gérer le dosage et les effets secondaires – Entretien

0.75 CMEs
A discussion on lithium dosing and side effect management in bipolar disorder, covering therapeutic levels, renal protection strategies, weight gain mechanisms, nephrogenic diabetes insipidus, cognitive effects, tremor differentiation, and dermatologic complications with practical solutions for clinical challenges.
David Osser, M.D.
Harvard Medical School
40.01 minutes d'interview audio

[FR] Quick Take Vol. 82

0.50 CMEs
What are the six key tips for switching oral antipsychotics? Does deprescribing antipsychotics after delirium improve outcomes in older adults? Why is xylazine overdose difficult to treat? What does the PAX-D study reveal about pramipexole for depression? Do bioequivalent medications always produce equivalent clinical results?
Faculté: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Paul Zarkowski, M.D., Scott R. Beach, M.D., Oliver Freudenreich, M.D., Derick E. Vergne, M.D.
36.44 minutes en 5 sections audio

Rétrospective 2025 : Approbations de la FDA, recommandations de pratique et modifications d’étiquetage en psychiatrie

0.50 CMEs
This guide provides a comprehensive overview of 2025’s key regulatory and guideline updates in psychiatry, covering new FDA approvals, label changes, and practice guidelines across depression, schizophrenia, addiction, neurocognitive disorders, and neurodevelopmental conditions, emphasizing practical implementation considerations for clinicians.
Sebastián Malleza, M.D.
Psychopharmacology Institute
Afficher plus d'informations

Psychotropic-Induced Movement Disorders and Cognitive Side Effects (Update) – fr

1.25 CMEs
A review of drug-induced movement disorders and cognitive side effects from psychotropic medications. The presentation covers diagnostic criteria, management strategies, and evidence-based treatments for akathisia, extrapyramidal symptoms, tardive dyskinesia, and medication-induced tremors.
Gregory Pontone, M.D., M.H.S.
University of Florida College of Medicine
69.02 minutes en 10 sections

Explorez notre bibliothèque de plus de 480 conférences vidéo, podcasts, résumés de recherche et entretiens avec des experts.

Informations sur le CME

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

Lost as a newly-matched psychiatry resident?

Access ALL our products FREE for 3 months!